Compare
Ocugen, Inc. vs Prime Medicine, Inc. vs CG Oncology, Inc. vs Zeo ScientifiX, Inc.
| Latest fiscal year | Ocugen, Inc. OCGN | Prime Medicine, Inc. PRME | CG Oncology, Inc. CGON | Zeo ScientifiX, Inc. ZEOX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-10-31 |
| Revenue | $4.41M | $4.63M | $4.04M | $5.20M |
| Revenue growth (YoY) | +8.8% | +55.3% | +254.7% | +12.5% |
| Gross margin | n/a | n/a | n/a | 82.1% |
| Operating margin | n/m | n/m | n/m | -103.6% |
| Net margin | n/m | n/m | n/m | -106.2% |
| Net income | -$67.85M | -$201.14M | -$161.00M | -$5.52M |
| EPS (Diluted) | n/a | -$1.35 | -$2.08 | -$0.86 |
| Operating cash flow | -$56.96M | -$162.56M | -$132.35M | -$718.0K |
| Free cash flow | -$57.15M | -$167.09M | -$132.48M | -$741.0K |
| Cash & equivalents | n/a | $63.03M | $32.49M | n/a |
| Total assets | $43.52M | $342.73M | $791.59M | $1.53M |
| Total liabilities | $55.68M | $221.87M | $38.99M | $2.95M |
| Shareholders' equity | -$12.17M | $120.87M | $752.60M | -$1.42M |
| Return on year-end equity | n/a | -166.4% | -21.4% | n/a |
| Shares outstanding | 312.38M | 180.51M | 80.69M | 6.75M |
Revenue, most recent five fiscal years
| Fiscal year | Ocugen, Inc. | Prime Medicine, Inc. | CG Oncology, Inc. | Zeo ScientifiX, Inc. |
|---|---|---|---|---|
| Latest | $4.41M Ended 2025-12-31 | $4.63M Ended 2025-12-31 | $4.04M Ended 2025-12-31 | $5.20M Ended 2025-10-31 |
| 1 year earlier | $4.05M Ended 2024-12-31 | $2.98M Ended 2024-12-31 | $1.14M Ended 2024-12-31 | $4.62M Ended 2024-10-31 |
| 2 years earlier | $6.04M Ended 2023-12-31 | $0 Ended 2023-12-31 | $204.0K Ended 2023-12-31 | $4.56M Ended 2023-10-31 |
| 3 years earlier | $2.49M Ended 2022-12-31 | $0 Ended 2022-12-31 | n/a | $6.49M Ended 2022-10-31 |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | n/a | $5.60M Ended 2021-10-31 |